Search results
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 1 day agoGlobal vaccine and drugmaker GSK asked the FDA in February to expand approval beyond adults 60 and...
FDA Advisers Recommend Omicron-Focused COVID Boosters for Fall
Homenewshere.com· 3 days agoFDA advisers recommended that the new COVID-19 boosters for fall target the Omicron variant, which...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 2 days ago"Recall that consumer hesitancy regarding Covid boosters has been driven in part by fears about...
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
Zacks via Yahoo Finance· 5 days agoAn FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to...
How Moderna’s newly approved RSV vaccine could impact 2024 revenue - Boston Business Journal
The Business Journals· 6 days ago(Nasdaq: MRNA) notched its second-ever FDA product approval, this time for its mRNA vaccine for...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoModerna also recently gained FDA approval for its second product, the RSV shot. In older adults, the...
Novavax, With A 369% Gain, Reverses Bullish Gains After Key FDA Move
Investor's Business Daily· 2 days agobooster to target the JN.1 variant, in line with the FDA Vaccines and Related Biological ...Moderna...
Novavax's stock surges almost 300% in the past month
Yahoo Finance· 2 days agovaccine for full approval. Until now, Novavax's COVID-19 vaccine has only been available through an emergency use authorization (EUA) ...
Should You Pick Moderna Stock At $150 After 25% Gains In A Month?
Forbes· 2 days agoModerna has a couple of factors to back its strong run. Firstly, the U.S. FDA recently approved...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...